AbBiBench: A Benchmark for Antibody Binding Affinity Maturation and Design

• URL: http://arxiv.org/abs/2506.04235v2
• Date: Fri, 10 Oct 2025 23:13:44 GMT
• Title: AbBiBench: A Benchmark for Antibody Binding Affinity Maturation and Design
• Authors: Xinyan Zhao, Yi-Ching Tang, Akshita Singh, Victor J Cantu, KwanHo An, Junseok Lee, Adam E Stogsdill, Ibraheem M Hamdi, Ashwin Kumar Ramesh, Zhiqiang An, Xiaoqian Jiang, Yejin Kim,
• Abstract summary: AbBiBench is a benchmarking framework for antibody binding affinity maturation and design.<n>It evaluates an antibody design's binding potential by measuring how well a protein model scores the full Ab-Ag complex.
• Score: 8.195812610020203
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: We introduce AbBiBench (Antibody Binding Benchmarking), a benchmarking framework for antibody binding affinity maturation and design. Unlike previous strategies that evaluate antibodies in isolation, typically by comparing them to natural sequences with metrics such as amino acid recovery rate or structural RMSD, AbBiBench instead treats the antibody-antigen (Ab-Ag) complex as the fundamental unit. It evaluates an antibody design's binding potential by measuring how well a protein model scores the full Ab-Ag complex. We first curate, standardize, and share more than 184,500 experimental measurements of antibody mutants across 14 antibodies and 9 antigens-including influenza, lysozyme, HER2, VEGF, integrin, Ang2, and SARS-CoV-2-covering both heavy-chain and light-chain mutations. Using these datasets, we systematically compare 15 protein models including masked language models, autoregressive language models, inverse folding models, diffusion-based generative models, and geometric graph models by comparing the correlation between model likelihood and experimental affinity values. Additionally, to demonstrate AbBiBench's generative utility, we apply it to antibody F045-092 in order to introduce binding to influenza H1N1. We sample new antibody variants with the top-performing models, rank them by the structural integrity and biophysical properties of the Ab-Ag complex, and assess them with in vitro ELISA binding assays. Our findings show that structure-conditioned inverse folding models outperform others in both affinity correlation and generation tasks. Overall, AbBiBench provides a unified, biologically grounded evaluation framework to facilitate the development of more effective, function-aware antibody design models.

Related papers

• Exploring Protein Language Model Architecture-Induced Biases for Antibody Comprehension [24.38887522188594]
  We investigate how architectural choices in protein language models (PLMs) influence their ability to comprehend antibody sequence characteristics and functions.<n>We evaluate three state-of-the-art PLMs-AntiBERTa, BioBERT, and ESM2--against a general-purpose language model (GPT-2) baseline on antibody target specificity prediction tasks.<n>Our results demonstrate that while all PLMs achieve high classification accuracy, they exhibit distinct biases in capturing biological features such as V gene usage, somatic hypermutation patterns, and isotype information.
  arXiv  Detail & Related papers  (2025-12-10T18:22:51Z)
• AbRank: A Benchmark Dataset and Metric-Learning Framework for Antibody-Antigen Affinity Ranking [3.6572710422983445]
  AbRank is a large-scale benchmark and evaluation framework that reframes affinity prediction as a pairwise ranking problem.<n>We introduce WALLE-Affinity, a graph-based approach that integrates protein language model embeddings with structural information to predict pairwise binding preferences.
  arXiv  Detail & Related papers  (2025-06-21T23:34:46Z)
• Llama-Affinity: A Predictive Antibody Antigen Binding Model Integrating Antibody Sequences with Llama3 Backbone Architecture [2.474908349649168]
  We present an advanced antibody-antigen binding affinity prediction model (Llamafinity)<n>The model achieved an accuracy of 0.9640, an F1-score of 0.9643, a precision of 0.9702, a recall of 0.9586, and an AUC-ROC of 0.9936.<n>This strategy unveiled higher computational efficiency, with a five-fold average cumulative training time of only 0.46 hours.
  arXiv  Detail & Related papers  (2025-05-17T20:10:54Z)
• dyAb: Flow Matching for Flexible Antibody Design with AlphaFold-driven Pre-binding Antigen [52.809470467635194]
  Development of therapeutic antibodies heavily relies on accurate predictions of how antigens will interact with antibodies.<n>Existing computational methods in antibody design often overlook crucial conformational changes that antigens undergo during the binding process.<n>We introduce dyAb, a flexible framework that incorporates AlphaFold2-driven predictions to model pre-binding antigen structures.
  arXiv  Detail & Related papers  (2025-03-01T03:53:18Z)
• Leveraging Large Language Models to Predict Antibody Biological Activity Against Influenza A Hemagglutinin [0.15547733154162566]
  We develop an AI model for predicting the binding and receptor blocking activity of antibodies against influenza A hemagglutininin (HA) antigens.<n>Our models achieved an AUROC $geq$ 0.91 for predicting the activity of existing antibodies against seen HAs and an AUROC of 0.9 for unseen HAs.
  arXiv  Detail & Related papers  (2025-02-02T06:48:45Z)
• Relation-Aware Equivariant Graph Networks for Epitope-Unknown Antibody Design and Specificity Optimization [61.06622479173572]
  We propose a novel Relation-Aware Design (RAAD) framework, which models antigen-antibody interactions for co-designing sequences and structures of antigen-specific CDRs.<n> Furthermore, we propose a new evaluation metric to better measure antibody specificity and develop a contrasting specificity-enhancing constraint to optimize the specificity of antibodies.
  arXiv  Detail & Related papers  (2024-12-14T03:00:44Z)
• Antigen-Specific Antibody Design via Direct Energy-based Preference Optimization [51.28231365213679]
  We tackle antigen-specific antibody sequence-structure co-design as an optimization problem towards specific preferences. We propose direct energy-based preference optimization to guide the generation of antibodies with both rational structures and considerable binding affinities to given antigens.
  arXiv  Detail & Related papers  (2024-03-25T09:41:49Z)
• xTrimoABFold: De novo Antibody Structure Prediction without MSA [77.47606749555686]
  We develop a novel model named xTrimoABFold to predict antibody structure from antibody sequence. The model was trained end-to-end on the antibody structures in PDB by minimizing the ensemble loss of domain-specific focal loss on CDR and the frame-aligned point loss.
  arXiv  Detail & Related papers  (2022-11-30T09:26:08Z)
• Incorporating Pre-training Paradigm for Antibody Sequence-Structure Co-design [134.65287929316673]
  Deep learning-based computational antibody design has attracted popular attention since it automatically mines the antibody patterns from data that could be complementary to human experiences. The computational methods heavily rely on high-quality antibody structure data, which is quite limited. Fortunately, there exists a large amount of sequence data of antibodies that can help model the CDR and alleviate the reliance on structure data.
  arXiv  Detail & Related papers  (2022-10-26T15:31:36Z)
• Reprogramming Pretrained Language Models for Antibody Sequence Infilling [72.13295049594585]
  Computational design of antibodies involves generating novel and diverse sequences, while maintaining structural consistency. Recent deep learning models have shown impressive results, however the limited number of known antibody sequence/structure pairs frequently leads to degraded performance. In our work we address this challenge by leveraging Model Reprogramming (MR), which repurposes pretrained models on a source language to adapt to the tasks that are in a different language and have scarce data.
  arXiv  Detail & Related papers  (2022-10-05T20:44:55Z)
• AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation [53.43922443725598]
  We present AntBO: a Combinatorial optimisation algorithm enabling efficient in silico design of the CDRH3 region. To benchmark AntBO, we use the Absolut! software suite as a black-box oracle because it can score the target specificity and affinity of designed antibodies in silico. In under 200 protein designs, AntBO can suggest antibody sequences that outperform the best binding sequence drawn from 6.9 million experimentally obtained CDRH3s.
  arXiv  Detail & Related papers  (2022-01-29T12:03:04Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.